About Alvotech
https://www.alvotech.comAlvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
CEO
Vilhelm Robert Wessman
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 57
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:4.35M
Value:$21.74M
BRACEBRIDGE CAPITAL, LLC
Shares:2.71M
Value:$13.53M
OAKTREE CAPITAL MANAGEMENT LP
Shares:1.56M
Value:$7.82M
Summary
Showing Top 3 of 69
About Alvotech
https://www.alvotech.comAlvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $113.95M ▼ | $77.56M ▼ | $-5.22M ▼ | -4.58% ▼ | $-0.02 ▼ | $3.69M ▼ |
| Q2-2025 | $173.24M ▲ | $81.36M ▲ | $32.04M ▼ | 18.49% ▼ | $0.11 ▼ | $51.74M ▼ |
| Q1-2025 | $132.76M ▼ | $56.74M ▼ | $109.68M ▲ | 82.61% ▲ | $0.39 ▲ | $137.22M ▲ |
| Q4-2024 | $151.21M ▲ | $57.4M ▲ | $-66.97M ▼ | -44.29% ▼ | $-0.22 ▼ | $-119.98M ▼ |
| Q3-2024 | $102.89M | $50.35M | $-11.39M | -11.07% | $-0.04 | $138.22M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $42.85M ▼ | $1.41B ▲ | $1.59B ▲ | $-176.76M ▼ |
| Q2-2025 | $151.45M ▲ | $1.39B ▲ | $1.57B ▲ | $-173.33M ▲ |
| Q1-2025 | $38.54M ▼ | $1.25B ▲ | $1.55B ▼ | $-302.29M ▲ |
| Q4-2024 | $51.43M ▼ | $1.22B ▼ | $1.63B ▲ | $-412.77M ▼ |
| Q3-2024 | $118.27M | $1.23B | $1.58B | $-343.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.25M ▼ | $-55.58M ▼ | $-39.45M ▼ | $-13.24M ▼ | $-108.6M ▼ | $-74.5M ▼ |
| Q2-2025 | $32.04M ▼ | $55.74M ▲ | $-28.6M ▼ | $83.15M ▲ | $112.91M ▲ | $42.12M ▲ |
| Q1-2025 | $109.68M ▲ | $12.55M ▲ | $-20.39M ▲ | $-5.84M ▼ | $-12.88M ▲ | $-10.82M ▲ |
| Q4-2024 | $-66.97M ▼ | $-39.2M ▲ | $-31.05M ▼ | $4.3M ▼ | $-66.85M ▼ | $-70.25M ▲ |
| Q3-2024 | $-11.39M | $-71.64M | $22.75M | $155.83M | $107.33M | $-85.46M |
CEO
Vilhelm Robert Wessman
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 57
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:4.35M
Value:$21.74M
BRACEBRIDGE CAPITAL, LLC
Shares:2.71M
Value:$13.53M
OAKTREE CAPITAL MANAGEMENT LP
Shares:1.56M
Value:$7.82M
Summary
Showing Top 3 of 69